Dergiler / Turkish Computational and Theoretical Chemistry / 2026 / Volume: 10 Issue: 2

Identification of 2-(piperazine _1_yl) _H_benzo[d] imidazole derivatives as a potent EGFR inhibitor by Virtual Screening and Molecular Dynamic Simulation

Samer Jasim(Imam Jaafar Al Sadiq University)0009-0000-6004-2120
Amani Amer Tawfeeq(Mustansiriyah University)0000-0003-3490-3593
Wathiq Al-hachami(Mustansiriyah University)0000-0001-7127-7136
Monther Faisal(Mustansiriyah University)0000-0002-2069-4121
Sayfa
—
Yayın Tarihi
2026-05-17
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

To establish its potential, additional laboratory tests are suggested.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Cancer remains to be among the major health issues in the global context, and safe and more efficient treatment is sought to be identified.
📊
Temel Bulgular & Veri:EGFR, or Epidermal Growth Factor Receptor, is a promising target of one of the strategies aimed at the survival and growth of cancer cells.
💡
Sonuç & Katkı:To establish its potential, additional laboratory tests are suggested.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Imidazole · EGFR inhibitors · Gefitinib

Abstract

Cancer remains to be among the major health issues in the global context, and safe and more efficient treatment is sought to be identified. EGFR, or Epidermal Growth Factor Receptor, is a promising target of one of the strategies aimed at the survival and growth of cancer cells. We have investigated, in this study, a set of more recently designed 2-(piperazin -1-yl)- 1H -benzo[d]imidazole derivatives through computer-based methods to determine their potential as EGFR inhibitors. The stability of the most promising complex was tested by the molecular dynamics simulation after molecular docking was used to predict the binding affinity of these compounds to EGFR. Other drug-like characteristics that were also looked at include absorption, bioavailability, and chemical suitability. Out of the tested compounds, one of them specifically the compound marked as A4 was interesting as it demonstrated high binding affinity, desirable pharmacokinetic properties, and a stable interaction with EGFR. The above findings indicate that compound A4 is a promising anti-cancer drug to be developed further. To establish its potential, additional laboratory tests are suggested.

🔖

Bu Makaleye Atıf Yap

Jasim, S., Tawfeeq, A. A., Al-hachami, W., Faisal, M. (2026). Identification of 2-(piperazine _1_yl) _H_benzo[d] imidazole derivatives as a potent EGFR inhibitor by Virtual Screening and Molecular Dynamic Simulation. Turkish Computational and Theoretical Chemistry, Volume: 10 Issue: 2. https://doi.org/10.33435/tcandtc.1632516

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (21)

  1. R. Kaur, A. Bhardwaj, S. Gupta, Cancer treatment therapies: traditional to modern approaches to combat cancers, Molecular Biology Reports, 50 (2023) 9663–9676.
  2. H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA: a cancer journal for clinicians, 71(2021) 209–249.
  3. J.S. Brown, S.R. Amend, R.H. Austin, R.A. Gatenby, E.U. Hammarlund, K.J. Pienta, Updating the Definition of Cancer, Molecular Cancer Research, 21 (2023) 1142–1147.
  4. S.M. Alzahrani, H.A. Al Doghaither, A.B. Al-Ghafar, General insight into cancer: An overview of colorectal cancer (review), Molecular and clinical oncology, 15 (2021) 1–8.
  5. J. Ferlay, M. Colombet, I. Soerjomataram, D.M. Parkin, M. Piñeros, A. Znaor, F. Bray, Cancer statistics for the year 2020: An overview, International journal of cancer, 149 (2021) 778–789.
  6. A. Lewandowska, G. Rudzki, T. Lewandowski, M. Próchnicki, S. Rudzki, B. Laskowska, J. Brudniak, Quality of Life of Cancer Patients Treated with Chemotherapy, International Journal of Environmental Research and Public Health, 17 (2020) 6938.
  7. W. Cao, H. Da. Chen, Y.W. Yu, N. Li, W.Q. Chen, Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020, Chinese medical journal,134 (2021) 783–791.
  8. I. de Lázaro, D.J. Mooney, Obstacles and opportunities in a forward vision for cancer nanomedicine, Nature Materials, 20 (2021) 1469–1479.
  9. J.L. Liang, G.F. Luo, W.H. Chen, X.Z. Zhang, Recent Advances in Engineered Materials for Immunotherapy-Involved Combination Cancer Therapy, Advanced Materials, 33 (2021) 2007630.
  10. J. Chu, F. Gao, M. Yan, S. Zhao, Z. Yan, B. Shi, Y. Liu, Natural killer cells: a promising immunotherapy for cancer, Journal of Translational Medicine, 20 (2022) 1–19.
  11. L. Zhong, Y. Li, L. Xiong, W. Wang, M. Wu, T. Yuan, W. Yang, C. Tian, Z. Miao, T. Wang, S. Yang, Small molecules in targeted cancer therapy: advances, challenges, and future perspectives, Signal Transduction and Targeted Therapy, 6 (2021) 1–48.
  12. S. Halder, S. Basu, S.P. Lall, A.K. Ganti, S.K. Batra, P. Seshacharyulu, Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023? Expert opinion on therapeutic targets, 27 (2023) 305–324.
  13. L. Xu, B. Xu, J. Wang, Y. Gao, X. He, T. Xie, X.Y. Ye, Recent advances of novel fourth generation EGFR inhibitors in overcoming C797S mutation of lung cancer therapy, European Journal of Medicinal Chemistry, 245 (2023) 114900.
  14. M. Sirico, A. D’Angelo, C. Gianni, C. Casadei, F. Merloni, U. De Giorgi, Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy, Cancers, 15 (2023) 703.
  15. A.S. Sony, X. Suresh, Molecular Modeling of Some Benzodiazole Derivatives with EGFR Protein 1M17, J. Pharm. Res. Int., 32 (2020) 84–95.
  16. Y.K. Tyagi, G. Jali, R. Singh, Synthesis and Anti-Cancer Applications of Benzimidazole Derivatives - Recent Studies, Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents, 22 (2022) 3280–3290.
  17. A.K. Wabdan, M.F. Mahdi, A.K. Khan, Molecular Docking, Synthesis and ADME Studies of New Pyrazoline Derivatives as Potential Anticancer Agents, Egyptian Journal of Chemistry, 64 (2021) 4311–4322.
  18. Y.T. Lee, Y.J. Tan, C.E. Oon, Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine, Acta Pharmaceutica Sinica B, 13 (2023) 478–497.
  19. W.I. El-Sofany, W.A. El-sayed, A.A. Abd-Rabou, M. El-Shahat, Synthesis of new imidazole-triazole-glycoside hybrids as anti-breast cancer candidates, Journal of Molecular Structure, 1270 (2022) 133942.
  20. B. Aruchamy, C. Drago, V. Russo, G.M. Pitari, P. Ramani, T.P. Aneesh, S. Benny, V.R.Vishnu, Imidazole-pyridine hybrids as potent anti-cancer agents, European Journal of Pharmaceutical Sciences, 180 (2023) 106323.
  21. I. Kufareva, R. Abagyan, Type-II kinase inhibitor docking, screening, and profiling using modified structures of active kinase states, Journal of medicinal chemistry, 51 (2008) 7921–7932.